1. Scrip
  2. >>Business

After IPO Success, Apogee Prepares To Take On Lilly And Sanofi Dupixent Across I&I

 
• By Andrew McConaghie

Using a 'de-risked business model' of targeting established drug categories with next-generation antibodies, Apogee is looking to take on Lilly’s lebrikizumab and Sanofi’s Dupixent.

Biotech

Apogee Therapeutics is one of just a handful of biopharma companies to successfully pull off an IPO this year, and will use the funds to fuel its challenge to Sanofi’s atopic dermatitis blockbuster, Dupixent, and Eli Lilly’s lebrikizumab.

Waltham, MA-based Apogee was launched at the end of last year as a spin-out from Paragon Therapeutics, with $169m and a handful of inflammation and immunology (I&I) drugs that are

Key Takeaways

  • Apogee’s IPO raised $345m, showing strong belief in its offering during the sector downturn

  • The company is going head-to-head with established I&I drugs, but aiming to best them with extended half life antobodies

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Japan Pharma Sees US Revenues Grow But Policy Impact Still Unclear

 
• By Lisa Takagi

Japanese majors put in generally solid performances in the fiscal year ended 31 March, but overseas revenues and forex effects, rather than the domestic market, provided most of the growth.

Pfizer Scoops 3SBio’s PD-1/VEGF Bispecific In ADC Combo Push

 
• By Dexter Jie Yan

Pfizer is doubling down on partnerships for combination therapies involving its antibody-drug conjugates through a new alliance with China's 3SBio’s for a bispecific antibody, potentially worth up to $6bn.

CRISPR Thinks Outside Gene-Editing Box With Sirius Deal

 
• By Alaric DeArment

The gene-editing company is making a deal with RNA interference-focused Sirius, but still focusing on cardiovascular disease, a major area of its pipeline.

HHS Intensifies Pressure On Pharma With MFN Pricing Benchmark

 
• By Jessica Merrill

The Trump administration released more details on “most favored nation” price targets drug companies are expected to apply to US drug prices.

More from Scrip

Asia Deal Watch: Lilly Partners With Rznomics On Hearing Loss

 
• By Joseph Haas, Xu Hu, Anju Ghangurde, and Lisa Takagi

Plus deals involving Minghui/Qilu, LENZ/Lotus, Amicus/Dimerix, Sanofi/Dr. Reddy’s, Henlius/Lotus, Apnimed/Desitin, Formosa/Saval, DAAN/GC Cell, VelaVigo/Ollin and Sol-Gel/Mayne.

Boehringer’s Next Generation IPF Drug Underwhelms

 
• By Andrew McConaghie

The company hoped its follow-up to blockbuster Ofev could clearly improve efficacy and safety benefits, but the full Phase III results from nerandomilast’s FIBRONEER-IPF fall short of a slam dunk.

Affimed’s ASCO ‘Hail Mary’ As Survival Chances Slim

 
• By Kevin Grogan

The German biotech has been forced into insolvency and NASDAQ suspension.